Antithrombotic

Antithrombotic

Marine polysaccharides

Published in Antonio Trincone, Enzymatic Technologies for Marine Polysaccharides, 2019

The sPS not only are potent anticoagulants, acting by directly increasing the clotting time by inhibiting the contact activation pathway (intrinsic pathway), but also show potent antithrombotic bioactivity by inhibiting the heparin cofactor II–mediated action of thrombin (Li et al. 2012). The activities of these sPSs have been connected to their chemical and structural features, the amount and distribution pattern of sulfate, the composition and distribution of monosaccharides and their glycosidic bonds, and also their molecular weight, which may play a major role in the coagulation and platelet aggregation processes (Li et al. 2008; Silva et al. 2010). Thus the higher the content of these factors, the higher the anticoagulant antithrombotic activity (Li et al. 2008; Silva et al. 2010; Li et al. 2012).

Antithrombotic therapy after transcatheter aortic valve implantation

View Article

Journal Information

Published in Expert Review of Medical Devices, 2022

Antonio Greco, Marco Spagnolo, Davide Capodanno

Antithrombotic therapy after TAVI is directed to prevent ischemic complications, which occur in a significant proportion of TAVI patients. Thrombus formation can be sustained by either or both platelet-mediated or thrombin-mediated mechanisms, constituting the rationale for the administration of antiplatelet agents and OAC, respectively. However, the major drawback of antithrombotic drugs is represented by bleeding events, which impose caution in the selection of the optimal regimen and consideration of individual patient comorbidities and risk profile.

Explore chapters and articles related to this topic

Marine polysaccharides

Antithrombotic therapy after transcatheter aortic valve implantation